M.D., Ph.D.
The Children's Hospital of Philadelphia Division of Oncology, 4028 CTRB 3501 Civic Center Boulevard

Pediatric Neuro-Oncology and Early Phase Clinic Trials/Developmental Therapeutics in Pediatric Brain Tumors. Particular interest in intratumoral hypoxia as a therapeutic target, a marker of treatment resistance, and a biomarker exploitable for non-invasive tumor imaging.

Signal transduction in embryonal tumors of the developing nervous system. Translating aberrantly expressed/activated neurodevelopmental signaling mechanisms into potential therapeutic targets

Early phase clinical trial development in pediatric central nervous system tumors. Targeting oncogenic signal transduction pathways and resistance mechanisms for therapeutic intervention.

Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2006– present)
Ph.D., Neurobiology, Yale University (1996)
M.D., Medicine, Yale University School of Medicine (1996)
M.Phil., Neurobiology, Yale University (1993)
B.S., Psychobiology, University of Southern California (1986)
Selected Publications
Iyer Radhika, Varela Carly R, Minturn Jane E, Ho Ruth, Simpson Anisha M, Light Jennifer E, Evans Audrey E, Zhao Huaqing, Thress Kenneth, Brown Jeffrey L, Brodeur Garrett M. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.. Cancer chemotherapy and pharmacology. Vol 70(3) . 2012 Sep:477-86.
Light Jennifer E, Koyama Hiroshi, Minturn Jane E, Ho Ruth, Simpson Anisha M, Iyer Radhika, Mangino Jennifer L, Kolla Venkatadri, London Wendy B, Brodeur Garrett M. Clinical significance of NTRK family gene expression in neuroblastomas.. Pediatric blood & cancer. Vol 59(2) . 2012 Aug:226-32.
Warren Katherine E, Gururangan Sri, Geyer J Russell, McLendon Roger E, Poussaint Tina Young, Wallace Dana, Balis Frank M, Berg Stacey L, Packer Roger J, Goldman Stewart, Minturn Jane E, Pollack Ian F, Boyett James M, Kun Larry E. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.. Journal of neuro-oncology. Vol 106(3) . 2012 Feb:643-9.
Norris Robin E, Minturn Jane E, Brodeur Garrett M, Maris John M, Adamson Peter C. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.. Cancer chemotherapy and pharmacology. Vol 68(6) . 2011 Dec:1469-75.
Minturn Jane E, Evans Audrey E, Villablanca Judith G, Yanik Gregory A, Park Julie R, Shusterman Suzanne, Groshen Susan, Hellriegel Edward T, Bensen-Kennedy Debra, Matthay Katherine K, Brodeur Garrett M, Maris John M. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.. Cancer chemotherapy and pharmacology. Vol 68(4) . 2011 Oct:1057-65.
Long Patrick M, Stradecki Holly M, Minturn Jane E, Wesley Umadevi V, Jaworski Diane M. Differential aminoacylase expression in neuroblastoma.. International journal of cancer. Journal international du cancer. Vol 129(6) . 2011 Sep:1322-30.
Ho Ruth, Minturn Jane E, Simpson Anisha M, Iyer Radhika, Light Jennifer E, Evans Audrey E, Brodeur Garrett M. The effect of P75 on Trk receptors in neuroblastomas.. Cancer letters. Vol 305(1) . 2011 Jun:76-85.